Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
A Road-to-Market Analysis for Non-Small Cell Lung Cancer Products: Tyrosine Kinase Inhibitors as a case study
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
- Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Enrico Tognana: European Medicines Agency, EMA, London, United Kingdom
Francesco Pignatti: European Medicines Agency, EMA, London, United Kingdom
Corinne De Vries: European Medicines Agency, EMA, London, United Kingdom
BackgroundsPre- and post- submission factors influence the Road-to-Market for medicinal products.
AimsThis work analysed the Road-to-Market for 10 NSCLC-TKIs products for which an MAA had been submitted.
The choice was based on the clinical relevance and potential identification of the most significant factors in the Road-to-Market for.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019